We prospectively examined the effect of antiepileptic (AED) cotherapy on steady state plasma concentrations of perampanel (PMP) in epileptic patients. We classi- 
| INTRODUCTION
Perampanel (PMP) is an antiepileptic drug (AED) authorized in Europe and the USA for adjunctive use in the treatment of focal onset seizures (FOS) with or without secondarily generalized seizures and primary generalized tonic-clonic seizures in patients aged ≥12 years. 1 It was approved by the US Food and Drug Administration in 2017 also as monotherapy for FOS with or without secondarily generalized seizures. 2 According to in vitro studies, PMP is extensively metabolized through cytochrome P450 CYP3A4/5 hepatic oxidation and sequential glucuronidation of inactive metabolites.
phase III clinical trials 3 and therapeutic drug monitoring (TDM) 4, 5 have shown that coprescribed CYP3A4 enzymeinducing AEDs, such as carbamazepine (CBZ), phenytoin (PHT), and oxcarbazepine (OXC), can significantly reduce (up to 50%-60%) plasma PMP concentrations. Conversely, the potential effect of enzyme inhibition on PMP metabolism is not clear. In vitro studies have shown a significant effect of ketoconazole, a potent inhibitor of CYP3A4 isoenzyme, on PMP pharmacokinetics, leading to a reduction of all metabolite formation. 6 On the contrary, coadministration of ketoconazole to healthy subjects resulted in a modest, around 20%, increase of PMP systemic exposure in a phase I drug interaction study. 6 From preliminary analyses, we suggested that valproic acid (VPA), a broad-spectrum enzyme inhibitor, 7 might increase PMP plasma concentrations in patients on chronic treatment. 8 The aim of our study was to confirm these preliminary findings in a larger series of patients with epilepsy treated with PMP.
| MATERIALS AND METHODS
The study design was multicenter, open, and prospective (protocol number 16179, approved by the ethics committee of the Bologna-Imola Local Health Trust). The protocol was proposed to patients with epilepsy treated with PMP. Written informed consent was obtained from each subject. Inclusion criteria were age ≥12 years, chronic PMP therapy for at least 1 month, and no change in dosage of PMP or concomitant AEDs over the preceding 3 weeks. Venous blood samples (3 mL) were drawn from patients between 9 and 12 AM, at approximately 12 hours after ingestion of a once-daily bedtime PMP dose. 1, 2 Blood specimens were transferred into heparinized tubes (16 IU heparin/mL blood) and centrifuged at 1700 g for 10 minutes at 4°C. Plasma was separated and stored at À30°C until analysis. PMP plasma concentrations were measured by high-pressure liquid chromatography with fluorescence detector, as previously described. 8 The lower limit of quantification and limit of detection were 20 and 10 ng/mL, respectively. Intra-and interassay imprecision and inaccuracy were ≤15% over the entire calibration range (20-1000 ng/mL). We classified AED comedication as: (1) An analysis of covariance was performed to assess the effect of age (≥18 vs <18 years) and sex on C/D of PMP. Comparisons of study variables among AED comedication subgroups were carried out by 1-way analysis of variance (ANOVA). Pairwise comparisons were performed by Holm-Sidak method when ANOVAs indicated a significant difference among subgroups. Sex distribution was compared among patient groups by chi-square test. Correlations between variables were assessed by Pearson product moment coefficient. Significance was set at P < .05. Analyses were carried out by SigmaPlot 13 software (Systat Software, San Jose, CA, USA). Data are expressed as mean AE standard deviation (SD).
| RESULTS
Between March 1, 2017 and February 27, 2018, we collected 114 plasma samples from 79 patients (42 females, 37 males) aged (mean AE SD) 33 AE 13 years (range = 12-66 years), with a body weight of 68 AE 21 kg (range = 25-114 kg). Mean PMP daily dose was 6.3 AE 2.3 mg (range = 2-12 mg/d). Twenty-eight patients (44 samples) were cotreated with enzyme inducers (group A), 21 (27 samples) with not strong enzyme inducers/not inhibitors (group B), 21 (31 samples) with not strong enzyme inducers/not inhibitors + VPA (group C), and 9 (12 samples) with enzyme inducers + VPA (group D; Table 1 ).
The 4 subgroups were comparable for sex and daily PMP dose; group D was significantly different from the other 3 groups for age and from groups A and B for weight (Table 1) . Plasma concentration of PMP ranged from 27.7 to 1232 ng/mL; the mean PMP concentration was 334 AE 253 ng/mL.
From a preliminary analysis of covariance, both age and sex were nonsignificant determinants of PMP C/D in our cohort of patients.
The relationship between weight-adjusted PMP dose and matched plasma concentration is depicted for each subgroup in Figure 1A . PMP plasma concentration exhibited dose linearity in groups A and C, whereas no significant correlation was found in the remaining 2 groups.
Mean PMP C/D was significantly (P < 0.001) reduced (À56%) in group A (1.79 AE 0.80) versus group B (4.05 AE 2.16) and increased in group C (6.72 AE 4.04) compared with groups A (+275%), B (+66%), and D (2.76 AE 2.00, +143%; Figure 1B ). From separate analyses in group A, mean values of C/Ds were similar in subgroups receiving CBZ (1.74 AE 0.67), PHT (1.67 AE 1.16), PB (1.37 AE 0.50), and OXC (2.08 AE 1.01). PMP C/Ds in group C were positively correlated with matched VPA daily doses (r = .577, P < .001) over a range of 500-2500 mg/d. Plasma concentrations of VPA were available Non-AED cotherapies were registered for 58 plasma samples (23 patients). Levothyroxine (10 samples) and proton pump inhibitors (8 samples) were the most frequently administered agents.
| DISCUSSION
In line with previous reports, [3] [4] [5] PMP C/D in the not strong enzyme inducer/not inhibitor + VPA comedicated group showed an increase of 66% and 275%, respectively, compared with the not strong enzyme inducer/not inhibitor and enzyme inducer subgroups. The combination of enzyme inducer + VPA seemed to outweigh inducing and inhibiting effects of comedication on PMP disposition. Compared with the data of Patsalos et al, 4 our mean PMP C/D was similar in not strong enzyme inducer/not inhibitor + VPA comedicated patients, whereas it turned out 33% lower in those receiving not strong enzyme inducers/not inhibitors without VPA. Differently from our results, these authors did not find a significant difference in mean PMP C/D between patients with and without VPA and concomitant not strong enzyme inducer/not inhibitor AEDs. Differences in study design (retrospective by Patsalos et al 4 vs prospective by us), patient population (only adult vs mixed adult and pediatric) and coadministered AED categorization (ie, topiramate classified as enzyme inducer vs not strong enzyme inducer/not inhibitor) might have contributed to this discrepancy. Conversely, comparisons between our findings and those recently reported in a cohort of Japanese patients on various AEDs are complicated because VPA was included among not enzyme inducer AEDs by these authors. 5 As pinpointed by Yamamoto et al, 5 PMP C/D in this patient group covered a wide range, partly explained by the possible contribution of genetic polymorphism of CYP3A5 isoform to PMP metabolism. In the light of our data, it could have been interesting to check whether the PMP C/Ds in the upper range were matched to VPA comedication. On the basis of PMP pharmacokinetic data from pooled phase III studies and in vitro metabolic experiments, a significant effect of VPA on PMP disposition was not anticipated. 3 PMP is reported to undergo metabolism primarily by CYP3A4/A5 isoenzymes, followed by glucuronide conjugation. 3 Valproic acid is known as a potent inhibitor of the activity of CYP2C9 in human liver microsomes, with only a slight inhibitory effect on CYP2C19 and CYP3A4 isoforms. 9 From in vivo studies, VPA has been found to F I G U R E 1 A, Correlation between perampanel plasma concentration and matched weight-adjusted daily dose by antiepileptic drug comedication subgroups: enzyme inducer, r = .693 (n = 44), P < .001; enzyme inducer + valproic acid (VPA), r = .434 (n = 12), P = not significant (NS; P > .05); not strong enzyme inducer/not inhibitor, r = À.06 (n = 27), P = NS; not strong enzyme inducer/not inhibitor + VPA, r = .390 (n = 31), P = .03. B, Scatter plot of plasma concentration to weight-adjusted daily dose ratio (C/D) of perampanel by antiepileptic comedication. Horizontal lines mark the mean value; capped bars indicate standard deviation. P < .001, overall significance of comparison among the 4 groups by 1-way analysis of variance; *significant difference from not strong enzyme inducer/not inhibitor and not strong enzyme inducer/ not inhibitor + VPA subgroups by Holm-Sidak method (P < .05); §significant difference from enzyme inducer, not strong enzyme inducer/not inhibitor, and enzyme inducer + VPA subgroups by Holm-Sidak method (P < .05) e106 | decrease the metabolic clearance of the CYP2C9 substrate PHT. 10 Moreover, clinical evidence pointed to its potent inhibitory effect on uridine diphosphate-glucanosyltransferase (UGT) 1A4 activity, accounting for the decreased metabolic clearance of coadministered LTG. 11 The inhibitory effects of VPA on CYP2C9 and UGT isoenzymes could also explain the clinically relevant reduction of PB metabolic clearance observed in patients with epilepsy. 12 More recently, VPA has been associated with a marked, dosedependent decrease of coprescribed rufinamide clearance. 13 Rufinamide is not a substrate of cytochrome P450 and is extensively metabolized via hydrolysis by carboxylesterases, 14 which should not be affected by VPA. The mechanism for this interaction remains unknown. 13 The mechanism of the possible pharmacokinetic interaction between PMP and VPA is unclear as well. Conversely, knowledge of PMP metabolic pathway is still limited, 3 and the contribution of isoforms other than CYP3A4/A5 cannot be ruled out.
1,2
In line with published TDM data, 4,5 a large interpatient variability was observed in the PMP plasma concentrationdose relationship, which might reflect the heterogeneous contribution of different types and doses of AED cotherapy. Moreover, the lack of a significant relationship between PMP plasma concentration and weight-adjusted drug daily dose in 2 of our patient subgroups might be ascribed to the narrow range of PMP doses coupled with the small number of plasma specimens, especially in the enzyme inducer + VPA group. One strength of our results is that they are the first prospectively collected in real life patients with the specific aim of assessing the effect of AED comedication on PMP disposition. Among the limitations is the relatively small number of enrolled patients, which was in any case comparable to the number of patients of previously published reports. 4, 5 Taken overall, these observations may have both clinical and theoretical relevance. Phase III studies have suggested a significant relationship between increase in PMP plasma concentrations and reduction in seizure frequency, but with a possible increase in adverse events. 15 The apparent effect of VPA on PMP C/D observed in our cohort of patients should be kept in mind in explaining signs of PMP toxicity in patients receiving complex AED cotherapy, including VPA. This effect was significantly related to VPA dosage, although we could not define any critical dose at which inhibition may be stronger. In selected cases, TDM of PMP could be helpful in disclosing the underlying pharmacokinetic interaction. Recognition of this interaction may be important also in titrating doses from the beginning of PMP treatment, or when reducing or withdrawing concomitant AEDs. PMP prescribing information recommends a slower titration (no more frequently than at 2-week intervals) in patients who are taking concomitant not strong enzyme inducer/not inhibitor compared with enzyme inducer AEDs (weekly intervals). 1, 16 Even slower PMP dose increases may be cautiously suggested in patients comedicated with not strong enzyme inducer/not inhibitor AEDs + VPA. Finally, from a theoretical point of view, evidence of the in vivo interaction between PMP and VPA could assist in designing in vitro studies to better characterize PMP metabolic pathways.
